Linked Life Data

19156339

Source:http://linkedlifedata.com/resource/pubmed/id/19156339

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-1-21
pubmed:abstractText
Male hypogonadism is characterised by decreased testicular function, especially testosterone deficiency. Its prevalence increases with age but may be acquired in all stages of life if it is not inborn. The lack of testosterone results in typical clinical symptoms. However, only about 10% of the affected men currently receive adequate treatment. A variety of testosterone preparations are available to meet the main needs of treatment, including intramuscular, transcutaneous, sublingual, and oral forms. In patients with prostate cancer, breast cancer, polycythemia, severe heart failure, obstruction of the lower urinary tract, or untreated sleep apnoea, testosterone treatment must be avoided. Therefore, clinical and laboratory screening are essential along with a long-term substitution.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1433-0563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
79-86; quiz 87
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Andrological testosterone replacement therapy].
pubmed:affiliation
Weiterbildungszentrum der European Academy of Andrology, Campus Leipzig, Klinik für Dermatologie, Venerologie und Allergologie der Universität Leipzig, Philipp-Rosenthal-Strasse 23-25, 04103 Leipzig. uwe.paasch@medizin.uni-leipzig.de
pubmed:publicationType
Journal Article, English Abstract, Review